title: Increased neutralizing antibody response after simultaneous immunization with leucogen and the feline leukemia virus transmembrane protein.
abstract: To develop improved vaccination strategies against feline leukemia virus (FeLV), rats were immunized with the transmembrane envelope protein p15E of FeLV alone or in combination with the commercial vaccine Leucogen® comprising the nonglycosylated FeLV surface envelope protein. Binding and neutralizing antibodies were induced in both groups and in the group immunized with Leucogen alone. Higher titers of antibodies neutralizing FeLV were induced by simultaneous immunization with Leucogen and p15E compared to the responses using Leucogen or p15E alone, suggesting that combination vaccines should be used in the future. Epitope mapping of p15E-specific antibodies induced by simultaneous immunization with Leucogen and p15E revealed the same pattern of response as obtained after immunization with p15E alone: one epitope was localized in the membrane-proximal external region (MPER) and the other in the fusion peptide-proximal region, and they are related to the epitopes detected after immunization with p15E of the porcine endogenous retrovirus and the koala retrovirus. The data indicate that these epitopes in the MPER are an effective target for neutralization and that antigens containing them may therefore prove to be a useful component of vaccines against retroviruses, including HIV-1.
authors.affiliation: Robert Koch Institute, Berlin, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Langhammer
authors.forename: Uwe
authors.initials: U
authors.lastname: Fiebig
authors.forename: Reinhard
authors.initials: R
authors.lastname: Kurth
authors.forename: Joachim
authors.initials: J
authors.lastname: Denner
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D018604:Epitope Mapping; D007114:Immunization / Q000379:methods*; D009500:Neutralization Tests; D051381:Rats; D017208:Rats, Wistar; D015682:Retroviridae Proteins, Oncogenic / Q000008:administration & dosage / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D015682:Retroviridae Proteins, Oncogenic; D014765:Viral Vaccines; C051525:feline leukemia virus protein p15E; C045569:feline leukemia virus vaccine